Oncology

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

125

total

725.353

impact factor

5.803

average impact factor

Group Leader: Diego Arango

team

zoom

download

During the year 2018 we have made significant contributions towards the understanding of the role of Myosin VI and Protein Kinase N in the oncogenic process of colon and gastric tumors, respectively, and two of our PhD students have defended their doctoral work on these topics. We have also reported the characterization of the complex mechanisms of inactivation of the tumor suppressor gene RHOA in colorectal cancer.

8

total

54^.967

impact factor

6^.871

average impact factor

SELECTED ARTICLES

Dopeso H, Rodrigues P, Bilic J, Bazzocco S, Cartón-García F, Macaya I, Jimenez L, Martínez-Barriocanal A, Nieto R, Schwartz S Jr. Mariadason JM, Arango D.
Mechanisms of Inactivation of the Tumor Suppressor Gene RHOA in Colorectal Cancer. British Journal of Cancer 2018;118:106–116. Dec 5. doi: 10.1038/bjc.2017.420.
Impact Factor: 5.9
Serrano-Candelas E, Ainsua-Enrich E, Navinés-Ferrer A, Rodrigues P, García-Valverde A, Bazzocco S, Macaya I, Arribas J, Serrano C, Sayós J, Arango D, Martin M.Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Mol Oncol. 2018 Jun 9. doi: 10.1002/1878-0261.12332. [Epub ahead of print] .
Impact Factor 5.3
Rafael D, Gener P, Andrade F, Seras-Franzoso J, Montero S, Fernández Y, Hidalgo M, Arango D, Sayós J, Florindo HF, Abasolo I, Schwartz S Jr, Videira M. AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against Cancer Stem Cells.
Drug Delivery 2018 Nov;25(1):961-972. doi: 10.1080/10717544.2018.1461276.
Impact Factor: 4.8
Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, Dávalos-Salas M, Chionh F, Murone C, Buchanan DD, Chatterton Z, Sieber OM, Arango D, Tebbutt NC, Williams D, Dhillon AS, Mariadason JM.
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Scientific Reports 2018 Jan 29;8(1):1767. doi: 10.1038/s41598-018-20176-9.
Impact Factor: 4.0
Rafael D, Martínez F, Andrade F, Seras-Franzoso J, Garcia-Aranda N, Gener P, Sayós J, Arango D, Abasolo I, Schwartz S Jr.
Efficient EFGR mediated siRNA delivery to Breast Cancer Cells by Cetuximab Functionalized Pluronic F127/Gelatin.Chemical Engineering Journal. 2018 May 15;340:81-93. DOI https://doi.org/10.1016/j.cej.2017.12.114
Impact Factor: 6.7

View all publications

Oncology

Overview

Publications

Group Leader: Diego Arango

Research Areas